Rigel Pharmaceuticals stock
RIGLNASDAQRigel Pharmaceuticals, Inc., HealthcareISIN US7665597024
71Score 71 out of 100, Strong
Price and trend
68 / 100
Price history
+14% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 22% above it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 45).
The price is 11% below its 52-week high. Largest decline in 20 years: 98% (January 2008 to November 2022).
Chart figures for advanced users
- SMA 50$47.52
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$37.54
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)45
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$25.44
- The lowest closing price of the last twelve months.
- Resistance$51.45
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Rigel Pharmaceuticals, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $860.34M, is number 204 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $294.28M (up 64.1% year on year) and earnings of $367.02M (up 1,999.1%).
- For fiscal 2026, analysts expect on average revenue of $305.73M (up 3.9%) and adjusted earnings per share of $3.43 (down 47.3%).
Show more
- MEQIRI Score 71 out of 100 (Strong): rank 121 of 714 in Healthcare, median 53.
- Our model puts fair value at $102.64, with the price 57% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High marginNet margin 100% over the last 12 months, Biotechnology median −93.3%.Profitability 99
- High return on capitalReturn on invested capital 91% in fiscal 2025, Biotechnology median −24.3%.Profitability 99
- Below fair valuePrice 57% below the fair value of $102.64.Valuation 95
Weaknesses
- Volatile share priceVolatility 55% a year over the last 12 months.
Its standout strengths are profitability and valuation, while fundamentals holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- high price swings
Valuation
Valuation signal
Significantly undervaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $73.32 and expensive above $171.07 (uncertainty high, based on the price swings of the past year).
Calculated with a cost of equity of 9.3%. At 10.3% the fair value would be $86.49, at 8.3% it would be $126.08.
Valuation metrics
From the cash-flow model alone; the profit includes one-off items, so there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 2.2% on the twelve months before. Revenue has grown strongly since 2009, at around 45% per year. From 2009 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 93%, operating 43%, net 125%. Last 12 months: net 100%. From 2009 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 2 Mar 2027in 110 days
- Last reported
- 5 Nov 2026EPS reported $0.65 (expected $0.87)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $3.430.0%
- Revenue
- $305.73M0.0%
- Earnings per share
- $4.580.0%
- Revenue
- $372.83M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +8.1%2026 revenue guidance raised and narrowed to about $285 million to $295 million with contract revenue lifted to about $30 million; positive full-year net income expected.
“We've raised and narrowed our guidance range and expect total revenues in the range of approximately $285 million-$295 million. Our guidance range includes our expectation of approximately $255 million-$265 million in net product sales, excluding VEPPANU, and approximately $30 million in contract revenues.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 4 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. One insider sold, $160,425 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Rigel Pharmaceuticals
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 71
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- 4D Molecular TherapeuticsFDMT $912.83M48
- Syndax PharmaceuticalsSNDX $863.37M33
- AnnexonANNX $857.49M37
- AlumisALMS $856.86M38
- Lexicon PharmaceuticalsLXRX $832.59M40
- Olema PharmaceuticalsOLMA $812.79M34
- Aura BiosciencesAURA $789.19M42
- ArdelyxARDX $786.8M34
ETFs that hold Rigel Pharmaceuticals
Held by 6 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Pharma Breakthrough UCITS ETFETLI | 2.61% | 0.49% | €26.29M |
| Avantis Global Small Cap Value UCITS ETFAVWS | 0.09% | 0.39% | €1.47B |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.06% | 0.35% | €1.21B |
Show 3 more
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.05% | 0.30% | €185.82M |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.03% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.03% | 0.30% | €2.17B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong since 10 Nov 2026, previously Neutral
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.